Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Tango Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Cambridge |
| Celcuity | 2026 | Post-IPO Debt | Undisclosed | Hamel |
| Jade Biosciences | 2026 | Post-IPO Equity | Undisclosed | Waltham |
| Mineralys Therapeutics | 2026 | Post-IPO Debt | Undisclosed | Radnor |
| ALX Oncology | 2026 | Post-IPO Debt | Undisclosed | San Francisco |
| Taysha Gene Therapies | 2026 | Post-IPO Equity | Undisclosed | Dallas |
| Helus Pharma | 2026 | Post-IPO Equity | Undisclosed | Toronto |
| Ollin Biosciences | 2026 | Series B | $100.0M | Austin |
| Contraline | 2026 | Series B | Undisclosed | Charlottesville |
| Dyne Therapeutics | 2026 | Post-IPO Debt | Undisclosed | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Tango Therapeutics | Post-IPO Equity | Undisclosed | Cambridge, United States |
| 2 | Celcuity | Post-IPO Debt | Undisclosed | Hamel, United States |
| 3 | Jade Biosciences | Post-IPO Equity | Undisclosed | Waltham, United States |
| 4 | Mineralys Therapeutics | Post-IPO Debt | Undisclosed | Radnor, United States |
| 5 | ALX Oncology | Post-IPO Debt | Undisclosed | San Francisco, United States |
| 6 | Taysha Gene Therapies | Post-IPO Equity | Undisclosed | Dallas, United States |
| 7 | Helus Pharma | Post-IPO Equity | Undisclosed | Toronto, Canada |
| 8 | Ollin Biosciences | Series B | $100.0M | Austin, United States |
| 9 | Contraline | Series B | Undisclosed | Charlottesville, United States |
| 10 | Dyne Therapeutics | Post-IPO Debt | Undisclosed | Cambridge, United States |
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
Contraline is a clinical-stage biotechnology company that develops male contraceptive solutions.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.
Moderna Therapeutics is a biotechnology company that develops medicines and vaccines based on messenger RNA (mRNA) technology.
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
SonoThera develops ultrasound-based technologies for delivering genetic therapies to targeted tissues.
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Secretome Therapeutics is a clinical-stage cell therapy company that develops therapies for rare cardiac diseases.
cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
RA Capital Management has invested in 282 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 15 different industry categories.
Among tracked funding rounds, Parabilis Medicines received $305.0M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 282 companies.
Recent RA Capital Management portfolio additions include Tango Therapeutics, Celcuity, Jade Biosciences, Mineralys Therapeutics, ALX Oncology. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors